+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dyslipidemia - Pipeline Review, H1 2019

  • ID: 4772671
  • Drug Pipelines
  • 338 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • BCWorld Pharm Co Ltd
  • Corvidia Therapeutics Inc
  • Gemphire Therapeutics Inc
  • InStar Technologies AS
  • Nippon Chemiphar Co Ltd
  • MORE
Dyslipidemia - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2019, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 27, 16, 19, 1, 34, 6 and 5 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • BCWorld Pharm Co Ltd
  • Corvidia Therapeutics Inc
  • Gemphire Therapeutics Inc
  • InStar Technologies AS
  • Nippon Chemiphar Co Ltd
  • MORE
Introduction

Dyslipidemia - Overview

Dyslipidemia - Therapeutics Development

Dyslipidemia - Therapeutics Assessment

Dyslipidemia - Companies Involved in Therapeutics Development

Dyslipidemia - Drug Profiles

Dyslipidemia - Dormant Projects

Dyslipidemia - Discontinued Products

Dyslipidemia - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Dyslipidemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Dyslipidemia - Pipeline by AbbVie Inc, H1 2019

Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2019

Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2019

Dyslipidemia - Pipeline by Amarin Corp Plc, H1 2019

Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2019

Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2019

Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2019

Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2019

Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2019

Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H1 2019

Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2019

Dyslipidemia - Pipeline by Cardax Inc, H1 2019

Dyslipidemia - Dormant Projects, H1 2019

Dyslipidemia - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Dyslipidemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Acasti Pharma Inc
  • Akcea Therapeutics Inc
  • Amarin Corp Plc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • BCWorld Pharm Co Ltd
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • Cadila Pharmaceuticals Ltd
  • Cardax Inc
  • Celon Pharma SA
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Corvidia Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Eli Lilly and Co
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • Golden Biotechnology Corp
  • Handok Inc
  • Hanlim Pharm Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Inovio Pharmaceuticals Inc
  • InStar Technologies AS
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • Kotobuki Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • LG Chem Ltd
  • LipimetiX Development Inc
  • Matinas BioPharma Holdings Inc
  • Mochida Pharmaceutical Co Ltd
  • Nippon Chemiphar Co Ltd
  • NorthSea Therapeutics BV
  • Novartis AG
  • NuSirt Biopharma Inc
  • Omeros Corp
  • Pharmena SA
  • Regeneron Pharmaceuticals Inc
  • Sancilio & Company Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • SJT Molecular Research SL
  • Suzhou Ribo Life Sciences Co Ltd
  • Viking Therapeutics Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll